Timolol Maleate — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	Ophthalmic (topical)	1 drop of 0.25% or 0.5% solution	q12h (every 12 hours)	Duration: Long-term, as needed Notes: May be used in combination with other glaucoma medications. Monitor IOP regularly. Use with caution in patients with asthma or heart disease.
Cat	Ophthalmic (topical)	1 drop of 0.25% or 0.5% solution	q12h (every 12 hours)	Duration: Long-term, as needed Notes: Use with caution due to risk of bronchoconstriction. Consider alternative if respiratory disease present.
Horse	Ophthalmic (topical)	1-2 drops of 0.5% solution	q12h (every 12 hours)	Duration: Long-term, as needed Notes: May be used in combination with other glaucoma therapies. Monitor for systemic effects.
Rabbit	Ophthalmic (topical)	1 drop of 0.25% or 0.5% solution	q12h (every 12 hours)	Duration: As needed Notes: Limited data; use with caution.

Clinical Indications & Species Uses

General Indications

Reduction of intraocular pressure in glaucoma
Ocular hypertension

Dog (Canine)

Treatment of glaucoma (open-angle and closed-angle) to reduce intraocular pressure
Adjunct therapy for uveitis-associated secondary glaucoma

Cat (Feline)

Treatment of glaucoma (less commonly used due to potential respiratory side effects)
Adjunct therapy for ocular hypertension

Horse (Equine)

Treatment of equine recurrent uveitis-associated glaucoma
Reduction of intraocular pressure in glaucoma

Rabbit & Small Mammals

Treatment of glaucoma (experimental use)

Exotic & Other Species

May be used in some exotic species for glaucoma, but limited data

Pharmacology & Mechanism of Action

Drug Class: Beta-adrenergic blocking agent (non-selective) | Pharmacological Group: Ophthalmic beta-blocker

Mechanism of Action: Timolol is a non-selective beta-adrenergic receptor antagonist that blocks both beta-1 and beta-2 receptors. In the eye, it reduces aqueous humor production by inhibiting the beta-adrenergic receptors in the ciliary epithelium, thereby lowering intraocular pressure (IOP). It does not affect pupil size or accommodation.

Pharmacodynamics: Timolol reduces intraocular pressure in both normal and glaucomatous eyes. The onset of action is typically within 30 minutes, with peak effect at 1-2 hours, and the duration of action can last up to 24 hours. It is effective in lowering IOP by 20-30% from baseline in most patients. Chronic use may lead to slight loss of effect over time.

⚡ Pharmacokinetics Summary

Absorption: When applied topically to the eye, timolol is absorbed through the cornea and conjunctiva. Systemic absorption can occur via the nasolacrimal duct and nasal mucosa, leading to significant systemic levels if not properly administered.

Distribution: Timolol is distributed into the aqueous humor and ocular tissues. Systemically, it is widely distributed and crosses the blood-brain barrier to some extent.

Metabolism: Timolol is extensively metabolized in the liver, primarily by cytochrome P450 enzymes (CYP2D6).

Excretion: Metabolites and a small amount of unchanged drug are excreted in the urine. The elimination half-life is approximately 4 hours in humans, but may be longer in animals with hepatic or renal impairment.

Half-Life: Approximately 4 hours in humans; in dogs, the half-life is similar (3-4 hours) after systemic administration.

Bioavailability: Systemic bioavailability after ocular administration is low (about 50% of the dose is absorbed systemically if not using punctal occlusion), but can be significant enough to cause systemic effects.

Protein Binding: Low protein binding, approximately 10-20%.

Available Formulations & Strengths

Ophthalmic Solution 0.25%, 0.5% (Ophthalmic (topical))

Ophthalmic Gel (forming solution) 0.25%, 0.5% (Ophthalmic (topical))

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to timolol or any component of the formulation
Bronchial asthma or history of bronchospasm
Severe chronic obstructive pulmonary disease
Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock
In cats, use with caution or avoid in patients with respiratory disease

Warnings & Clinical Precautions:

Systemic absorption can occur; use with caution in animals with cardiovascular or respiratory disease.
May mask signs of hypoglycemia in diabetic animals.
Use with caution in animals with hepatic or renal impairment.
Do not use in animals with known hypersensitivity to beta-blockers.
In food animals, not approved for use; withdrawal times must be observed if used extra-label.
Monitor intraocular pressure regularly to assess efficacy.
If switching from another beta-blocker, taper gradually to avoid rebound hypertension.

Adverse Effects & Reactions

Common:

Transient stinging or burning on instillation
Blurred vision
Local irritation
Hyperemia (redness)

Serious / Severe:

Bronchospasm (especially in cats and animals with asthma)
Bradycardia
Hypotension
Heart block
Congestive heart failure exacerbation
Respiratory depression

Rare:

Corneal anesthesia
Dry eye (keratoconjunctivitis sicca)
Allergic reactions
Systemic beta-blockade effects (e.g., lethargy, depression)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Other beta-blockers (systemic or ophthalmic)	Additive beta-blockade, increased risk of bradycardia and hypotension	High
Calcium channel blockers (e.g., diltiazem, verapamil)	Additive negative inotropic and chronotropic effects, risk of AV block	High
Digoxin	Additive bradycardia and potential for heart block	Moderate
Epinephrine or sympathomimetics	May cause initial hypertensive response followed by bradycardia (unopposed alpha-adrenergic effects)	Moderate
Insulin or oral hypoglycemics	May mask signs of hypoglycemia (tachycardia, tremor)	Moderate
Cimetidine	May increase timolol plasma levels	Mild

Overdose & Toxicity Management

Signs of Toxicity:

Severe bradycardia
Hypotension
Bronchospasm
Cardiac failure
Respiratory depression
Seizures (in severe cases)

Emergency Treatment Protocol: Discontinue drug immediately. Provide symptomatic and supportive care. For severe bradycardia or hypotension, administer atropine (0.04 mg/kg IV) and consider beta-agonists (e.g., dobutamine, isoproterenol) if needed. For bronchospasm, use bronchodilators (e.g., albuterol). In cases of oral ingestion, consider gastric lavage and activated charcoal. Monitor cardiac and respiratory function closely.

Food Animal Withdrawal Times

Not approved for use in food animals. If used extra-label, follow AMDUCA guidelines and consult FARAD for specific withdrawal times. Generally, a withdrawal period of at least 30 days for meat and 7 days for milk is recommended, but this is not officially established.

Storage, Handling & Regulatory Information

Storage Temperature: Store at 15-30°C (59-86°F). Protect from freezing.

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Keep container tightly closed. Protect from light. Do not use if solution changes color or becomes cloudy.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for human use; not approved for veterinary use, but widely used in veterinary ophthalmology.

Extra-Label (Off-Label) Use: In the US, timolol is not FDA-approved for veterinary use, but it can be prescribed legally under the Animal Medicinal Drug Use Clarification Act (AMDUCA) for non-food animals. For food animals, extra-label use is prohibited unless a valid veterinarian-client-patient relationship exists and no approved alternative is available; withdrawal times must be established.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Timolol maleate is a cornerstone in the management of glaucoma in dogs and horses. It is often used as a first-line agent or in combination with other drugs such as carbonic anhydrase inhibitors (e.g., dorzolamide) or prostaglandin analogs (e.g., latanoprost). In cats, it is used less frequently due to the risk of bronchoconstriction; alternative beta-blockers like betaxolol (more cardioselective) may be considered. When administering, apply gentle pressure to the nasolacrimal duct for 1-2 minutes after instillation to reduce systemic absorption. Monitor heart rate and respiratory function, especially in animals with pre-existing cardiopulmonary disease. Regular tonometry is essential to assess efficacy. In cases of refractory glaucoma, surgical options may be considered. Always taper off beta-blockers gradually to avoid rebound ocular hypertension.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)